Xenobiotic metabolism in human skin and 3D human skin reconstructs: A review

Current Drug Metabolism

Volumn 8, Issue 8, 2007, Pages 758-772

  Gibbs, Sue ^a   van de Sandt, Johannes J M ^b   Merk, Hans F ^c   Lockley, David J ^d   Pendlington, Ruth U ^d   Pease, Camilla K ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNILEVER RESEARCH   (United Kingdom)

Author keywords

3D skin reconstructs; Cytochrome P450; IDO expression; In vitro skin absorption; Microarray; Peptidases

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; 2 NITRO 1,4 PHENYLENEDIAMINE; 4 AMINOPHENOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALPHA TOCOPHEROL; ATRAZINE; AZO REDUCTASE; CARNITINE; CINNAMALDEHYDE; CINNAMYL ALCOHOL; CLOBETASOL PROPIONATE; CYTOCHROME P450; ESTERASE; HYDROGEN PEROXIDE; MESSENGER RNA; NICOTINIC ACID ETHYL ESTER; OXYGENASE; PHENYLENEDIAMINE; PROPOXUR; PROPRANOLOL; RESORUFIN; RETINOIC ACID; RETINOL PALMITATE; T 2 TOXIN; TOXIC SUBSTANCE; TRICLOSAN; TRIOLEIN; UNINDEXED DRUG; XENOBIOTIC AGENT;

BIOTRANSFORMATION; CHEMICAL CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; ENZYME ASSAY; EX VIVO STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; NORTHERN BLOTTING; OCCUPATIONAL EXPOSURE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN ABSORPTION; SKIN ALLERGY; SKIN CANCER; SKIN CARCINOGENESIS; SKIN INFLAMMATION; SKIN SENSITIZATION; SKIN TOXICITY; TOXICOKINETICS; WESTERN BLOTTING; XENOBIOTIC METABOLISM;

BIOTRANSFORMATION; HUMANS; MODELS, BIOLOGICAL; SKIN; XENOBIOTICS;

EID: 36949000450     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920007782798225     Document Type: Review

References (94)

1. Mukhtar, H. and Bickers, D.R. (1981) Drug Metab. Dispos., 9(4), 311-314.
2. Hotchkiss, S.A.M. (1998) in Dermal Absorption and Toxicity Assessment, (Roberts M.S. and Walters K.A. Eds.), Marcel Dekker, New York, pp. 43-101.
3. Norden, G. (1953) Acta Pathol. Mic. Sc. Suppl., 96, 1-100.
4. Nohynek, G.J.; Duche, D.; Garrigues, A.; Meunier, P.A.; Toutain, H.; Leclaire, J. (2005) Toxicol. Lett. 158(3), 196-212.
5. Flamand, N.; Marrot, L.; Belaidi, J.P.; Bourouf, L.; Dourille, E.; Feltes, M. and Meunier, J.R. (2006) Mutat. Res., 606(1-2), 39-51.
6. Smith, C.K. and Hotchkiss, S.A.M. (2001) in Allergic Contact Dermatitis: Chemical and Metabolic Mechanisms, Taylor & Francis, pp89-117.
7. Mukhtar, H. and Khan, W.A. (1989) Drug Metab. Rev., 20(2-4), 657-673.
8. Zhu, Z.; Hotchkiss, S.A.; Boobis, A.R. and Edwards, R.J. (2002) Biochem. Bioph. Res. Commun., 297(1), 65-70.
9. Baron, J.M.; Zwadlo-Klarwasser, G.; Jugert, F.; Hamann, W.; Rubben, A.; Mukhtar, H.; and Mork, H.F.(1998) Biochem. Pharmacol., 56(9), 1105-1110.
10. Reaven, E.P. and Cox, A.J. (1965) J. Invest. Dermatol., 45, 422.
11. Kao, J.; Patterson, F.K. and Hall, J. (1985) Tox. Appl. Pharm., 81, 502-516.
12. Bronaugh, R.L. and Stewart, R.F. (1985) J. Pharm. Sci., 74, 64-67.
13. Collier, S.W.; Sheikh, N.M.; Sakr, A.; Lichtin, J.L.; Stewart, R.F. and Bronaugh, R.L. (1989) Tox. Appl. Pharm., 99(3), 522-533.
14. Friend, D.R. (1992) J. Control. Release, 18, 235-248.
15. Dick, I.P. and Scott, R.C. (1992) J. Pharm. Pharmacol., 44(8), 640-645.
16. Van de Sandt, J.J.M. (1994) Thesis, University of Utrecht, ISBN 90-393-0773-3.
17. Gibbs, S.; Vietsch, H.; Meier, U. and Ponec, M. (2002) Exp. Dermatol., 11, 217-223.
18. OECD Guidelines for the testing of chemicals (No. 428) (2001) Paris, France. Organisation for Economic Cooperation and Development.
19. Franz, T.J. (1975) J. Invest. Dermatol., 64, 190-195.
20. Van de Sandt, J.J.M.; Rutten, A.A.J.J.L. and Van Ommen, R. (1993) Tox. Appl. Pharm., 123, 144-150.
21. Cheung, C. and Smith Pease, C.K. (2004) in Comprehensive Handbook of Alcohol-Related Pathology, (Preedy, V. and Watson, R. Eds), Elsevier, London, Vol 1-3, Chapter 111
22. Turner S.M. (2006) J. Pharmacol. Toxicol. 53, 75-85.
23. Smiley, A.K.; Klingenberg, J.M.; Aronow, B.J.; Boyce, S.T.; Kitzmiller, W.J. and Supp, D.M. (2005) J. Invest. Dermatol. 125, 1286-1301.
24. Wester, R.C.; Christoffel, J.; Hartway, T.; Poblete, N.; Maibach, H.I. and Forsell, J. (1998) Pharm. Res., 15, 82-84.
25. Kemppainen, B.W.; Riley, R.T.; Pace, J.G. and Hoerr, F.J. (1986) Food Chem. Toxicol. 24, 221-227.
26. Hewitt, P.G.; Perkins, J. and Hotchkiss, S.A.M. (2000) Drug Metab. Dispos., 28, 748-754.
27. Tanojo, H.; Wester, R.C.; Shainhouse, J.Z. and Maibach, H.I. (1999) Eur. J. Drug Metab. Pharmacokinet., 24(4), 345-351.
28. Beckley Kartey, S.A.J.; Hotchkiss, S.A.M. and Capel, M. (1997) Tox. Appl. Pharm., 145(1), 34-42.
29. Gibson, G.G. and Skett, P. (2001) Introduction to Drug Metabolism (3rd Edtion), Nelson Thornes Ltd.
30. Edetox (2004). Final report (http://www.ncl.ac.uk/edetox/ current-position.html)
31. Ademola, J.I.; Chow, C.A.; Wester, R.C. and Maibach, H.I. (1993b). J. Pharm. Sci., 82, 767-770.
32. Ademola, J.I.; Wester, R.C. and Maibach, H.I.(1993c). Tox. Appl. Pharm., 121, 78-86.
33. Smith, C.K.; Moore, C.A.; Elahi, E.N.; Smart, A.T.S. and Hotchkiss, S.A.M. (2001) Tox. Appl. Pharm., 168, 189-199.
34. Katiyar, S.K.; Matsui, M.S. and Mukhtar, H. (2000) J Invest Dermatol., 114(2), 328-333.
35. Du, L.; Mernaugh, R. and Keeney, D.S. (2004) J. Invest. Dermatol., 122(3), A92, 548
36. Smith, G.; Dawe, R.S.; Clark, C.; Evans, A.T.; Comrie, M.M.; Wolf, C.R,; Ferguson, J.and Ibbotson, S.H. (2003) J. Invest. Dermatol., 121(2), 390-398.
37. Collier, S.W.; Storm, J.E. and Bronaugh, R.L. (1993) Toxicol. Appl. Pharm., 118, 73-79.
38. Boogaard, P.J.; Denneman, M.A. and Van Sittert, N.J. (2000) Xenobiotica, 30(5), 469-483.
39. Gysler, A.; Kleuser, B.; Sippl, W.; Lange, K.; Korting, H.C.; Holtje, H.D. and Korting, H.C. (1999) Pharm. Res., 16, 1386-1391.
40. Rittirod, T.; Hatanaka, T.; Uraki, A.; Hino, K.; Katayama, K. and Koizumi, T. (1999) Int. J. Pharm., 178, 161-169.
41. Boehnlein, J.; Sakr, A.; Lichtin, J.L. and Bronaugh, R.L. (1994) Pharm. Res., 11(8), 1155-1159.
42. Guzek, D.B.; Kennedy, A.H.; McNeil, S.C.; Wakshull, E. and Potts, R.O. (1989) Pharm. Res., 6, 33-39.
43. Ademola, J.I.; Sedik, L.E.; Wester, R.C. and Maibach, H.I. (1993a) Arch. Toxicol., 67, 85-91.
44. Liu, P.; Higuchi, W.I.; Ghanem, A.-H. and Good, W.R. (1994) Pharm. Res., 11, 1777-1784.
45. Van de Sandt, J.J.M.; Maas, W.J.M.; Doornink, P.C. and Rutten, A.A.J.J.L. (1995) Fund. Appl. Toxicol., 25, 20-28.
46. Moss, T.; Howes, D. and Williams, F.M. (2000) Food Chem. Toxicol., 38, 361-370.
47. Jewell, C.; Heylings, J.; Clowes, H.M. and Williams, F.M. (2000) Arch. Toxicol., 74, 356-365.
48. Yourick, J.J. and Bronaugh, R.L. (2000) Tax. Appl. Pharm., 166, 13-23.
49. Bell, E.; Sher, S.; Hull, B.; Merrill, C.; Rosen, S.; Chamson, A.; Asselineau, D.; Dubertret, L.; Coulomb, B.; Lapiere, C.; Nusgens, B. and Neveux, Y. (1983) J. Invest. Dermatol., 81, 2s-10s
50. El Ghalbzouri, A.; Lamme, E. and Ponec, M. (2002) Cell Tissue Res., 310, 189-199.
51. Nusgens, B.; Merrill, C.; Lapiere, C. and Bell, E. (1984) Collagen Rel. Res. 4, 351-363.
52. Ponec, M.; Boelsma, E.; Gibbs, S. and Mommaas, M. (2002b) Skin Pharmacol. Appl., 15(Suppl 1), 4-17.
53. Parenteau, N.L.; Nolte, C.M.; Bilbo, P.; Rosenberg, M.; Wilkins, L.M.; Johnson, E.W.; Watson, S.; Mason, V.S. and Bell, E. (1991) J. Cell Biochem., 45, 245-251.
54. Lindsay, C.D. and Upshall, D.G. (1995) Hum. Exp. Toxicol., 14, 580-586.
55. OECD Guidelines for the testing of chemicals (No. 431) (2002) Paris, France, Organisation for Economic Cooperation and Development.
56. Fentem, J.H. and Botham, P.A. (2002) ATLA, 30(Suppl. 2), 61-67.
57. Ponec, M.; Boelsma, E.; Gibbs, S. and Mommaas, M. (2002a) Skin Pharmacol. Appl., 15(Suppl 1), 4-17.
58. Cotovio, J.; Roguet, R.; Pion, F.X.; Rougier, A. and Leclaire, J. (1996) Skin Pharmacol., 9, 242-249.
59. Harris, I.R.; Siefken, W.; Beck-Oldach, K.; Brandt, M.; Wittern, K.P. and Pollet, D. (2002a) Skin Pharmacol. Appl., 15(Suppl 1), 59-67.
60. Raffali, F.; Rougier, A. and Roguet, R. (1994) Skin Pharmacol., 7, 345-354.
61. Neis, M.M.; Marquard, Y.; Joussen, S.; Heise, R.; Baron, J.M. and Merk, H.F. (2005) J. Invest. Dermatol., Suppl 125(3), A83.
62. Harris, I.R.; Siefken, W.; Beck-Oldach, K.; Wittern, K.P. and Pollet, D. (2002b) Skin Pharmacol. Appl., 15(Suppl 1), 68-73.
63. Ernesti, A.M.; Swiderek, M. and Gay, R. (1992) Skin Pharmacol., 5, 146-153.
64. Lehmann, B.; Genehr, T.; Knuschke, P.; Pietzsch, J. and Meurer, M. (2001) J. Invest. Dermatol., 117, 1179-1185.
65. Noblesse, E.; Cenizo, V.; Bouez, C.; Borel, A.; Gleyzal, C.; Peyrol, S.; Jacob, M.P.; Sommer, P. and Damour, O. (2004) J. Invest. Dermatol., 122, 621-630.
66. Mahns, A.; Wolber, R.; Stab, F.; Klotz, L.O. and Sies, H. (2004) Photochem. Photobiol. Sci., 3, 257-262.
67. Sarkhosh, K.; Tredget, E.E.; Karami, A.; Uludag, H.; Iwashina, T.; Kilani, R.T. and Ghahary, A. (2003) J. Cell Biochem., 90, 206-217.
68. Sarkhosh, K.; Tredget, E.E.; Uludag, H.; Kilani, R.T.; Karami, A.; Li, Y.; Iwashina, T. and Ghahary, A. (2004) J. Cell Physiol., 201 146-154.
69. Sugibayashi, K.; Hayashi, T.; Matsumoto, K. and Hasegawa, T. (2004) Drug Metab. Pharmacokinet., 19, 352-362.
70. Nabi, Z.; Tavakkol, A.; Dobke, M. and Polefka, T.G. (2001) Curr. Probl. Dermatol., 29, 175-186.
71. Perkins, M.A.; Osborne, R.; Rana, F.R.; Ghassemi, A. and Robinson, M.K. (1999) Toxicol. Sci., 48, 218-229.
72. Robinson, M.K.; Osborne, R. and Perkins, M.A. (2000) Ann. N. Y. Acad Sci., 919, 192-204.
73. Boyce, S.; Michel, S.; Reichert, U.; Shroot, B. and Schmidt, R. (1990) Skin Pharmacol., 3, 136-143.
74. Gibbs, S.; Silva Pinto, A.N.; Murli, S.; Huber, M.; Hohl, D. and Ponec, M. (2000) Wound Repair Regen., 8, 192-203.
75. Egelrud, T.; Regnier, M.; Sondell, B.; Shroot, B. and Schmidt, R. (1993) Acta Derm.-Venereol., 73, 181-184.
76. Cario-Andre, M.; Briganti, S.; Picardo, M.; Nikaido, O.; Gall, Y.; Ginestar, J. and Taieb, A. (2002) J. Photochem. Photobiol. B., 68, 79-87.
77. Coulomb, B.; Dubertret, L.; Bell, E.; Merrill, C.; Fosse, M.; Breton-Gorius, J.; Prost, C. and Touraine, R. (1983) J. Invest. Dermatol., 81, 75-78.
78. Mehul, B.; Corre, C.; Capon, C.; Bernard, D. and Schmidt, R. (2003) Exp. Dermatol., 12, 537-545.
79. Fletcher, S.T. and Basketter, D.A. (2006) Toxicol. In Vitro, 20(6), 975-85.
80. Baron, J.M.; Zwadlo-Klarwasser, G.; Sieben, S.; Rubben, A.; Jugert, F. and Merk, H.F. (1998). J. Invest. Dermatol., 110, 681.
81. Du, L.; Neis, M.M.; Ladd, P.A.; lLanza, D.L.; Yost, G.S. and Keeney, D.S. (2006). Tax. Appl. Pharm., 213(2), 135-144.
82. Merk, H.F.; Mukhtar, H.; Kaufmann, I.; Das, M. and Bickers, D.R. (1987). J. Invest. Dermatol., 88, 71-76.
83. Fox, L.P.; Merk, H.F. and Bickers, D.R. (2006) in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Bruntan, L.L.; Lazo, J.S. and Parker, K.l. Eds.), Mc Graw Hill, New York, pp. 1679-1706.
84. Swanson, H.I. (2004) Chem.-Biol. Interact., 149(2-3), 69-79.
85. Baron, J.M.; Heise, R.; Blaner, W.S.; Neis, M.; Joussen, S.; Dreuw, A.; Marquardt, Y.; Saurat, J.H.; Merk, H.F.; Bickers, D.R. and Jugert, F.K. (2005) J. Invest. Dermatol., 125(1), 143-153.
86. Heise, R.; Mey, J.; Neis, M.M.; Marquardt, Y.; Joussen, S.; Ott, H.; Wiederholt, T.; Kurschat, P.; Megahed, M.; Bickers, D.R.; Merk, H.F. and Baron, J.M.(2006) J. Invest. Dermatol., Jun 15 [Epub ahead of print].
87. Smith, G.; Ibbotson, S.H.; Cormie, M.M.; Dawe, R.S.; Bryden, A.; Ferguson, J. and Wolf, C.R. (2006) Brit. J. Dermatol., 155(2), 275-81.
88. Merk, H.F.; Abel, J.; Baron, J.M. and Krutmann, J. (2004). Tox. Appl. Pharm., 195, 267-277.
89. Yengi, L.G.; Xiang, Q.; Scantina, P.J.; Kao, J.; Ball, S.E.; Francillo, R.; Ferron, G. and Wolf, C.R. (2003). Anal. Biochem., 316, 103-110.
90. Faller, C.; Bracher, M.; Dami, N. and Roguet, R. (2002) Toxicol. In Vitro, 16, 557-572.
91. Facy, V.; Flouret, V.; Regnier, M. and Schmidt, R. (2005) Toxicol. In Vitro, 19, 787-795.
92. Rivier, M.;,Castiel, I.; Safonova, I.; Ailhaud, G. and Michel, S. (2000) J. Invest Dermatol., 114, 681-687.
93. Maury, E.; Prevost, M.C.; Nauze, M.; Redoules, D.; Tarroux, R.; Charveron, M.; Salles, J.P.; Perret, B.; Chap, H. and Gassama-Diagne, A. (2002) Biochem. Biophys. Res. Commun., 295, 362-369.
94. Ponec, M.; Kempenaar, J.; Weerheim, A.; de Lannoy, L.; Kalkman, I. and Jansen, H. (1995) Arch. Dermatol. Res., 287, 723-730.